WuXi XDC Cayman (HKSE:02268) Growth Rank : 0 (As of May. 13, 2024)

View and export this data going back to 2023. Start your Free Trial

What is WuXi XDC Cayman Growth Rank?

WuXi XDC Cayman has the Growth Rank of 0.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

WuXi XDC Cayman Growth Rank Related Terms

Thank you for viewing the detailed overview of WuXi XDC Cayman's Growth Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

WuXi XDC Cayman (HKSE:02268) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » WuXi XDC Cayman Inc (HKSE:02268) » Definitions » Growth Rank

Comparable Companies

Traded in Other Exchanges

L74:Germany

Address

No. 11 Xinhui Ring Road, Xinwu, Jiangsu, Wuxi, CHN

Website

WuXi XDC Cayman Inc is a leading CRDMO focused on the global ADC and broader bioconjugate market and the only one dedicated to providing integrated and end-to-end services. Leveraging expertise in both biologics and small molecules, It offers interdisciplinary and comprehensive services, covering bioconjugate discovery, research, development and manufacturing. The company provides these services from proximately located, state-of-the-art laboratories and manufacturing facilities, leading to the significant reduction of development timeline and costs. As a fully integrated one-stop bioconjugate discovery, development and manufacturing platform, its mission is to continuously enhance its platform, and propel and transform the development of the bioconjugate industry.

WuXi XDC Cayman (HKSE:02268) Headlines

No Headlines